Profile http://med.stanford.edu/profiles/Hugh_Solvason/ Email this page Printer friendly version

Key Documents

Hugh Solvason

Associate Professor - Med Center Line, Psychiatry & Behavioral Science - Psychopharmacology

Contact Information

Clinical Offices

Psychiatry Department 401 Quarry Rd Ste 2138 MC 5723 Stanford, CA 94305
Telephone Work (650) 723-8335 Fax (650) 723-8331

Clinical Focus

Psychiatry

Professional Education

University of Alabama School of Medicine AL
Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2001)
SUMC - Graduate Medical Education (1998) CA
SUMC - Graduate Medical Education (1997) CA
Stanford University Medical Center (1994) CA
University of Alabama School of Medicine (1993) AL

Clinical Trials

A Twelve Month, Open-Label, Safety Trial of Flibanserin 50 Milligrams to 100 Milligrams Daily in Women with Hypoactive Sexual Desire Disorder Recruiting
Repetitive Transcranial Magnetic Stimulation (rTMS) for treatment resistant bipolar depression No longer recruiting
Treatment of Schizoaffective Disorder Using Mifepristone Terminated
A safety and efficacy trial of flibanserin in premenopausal women with HSDD No longer recruiting

Publications

Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Greicius MD, Flores BH, Menon V, Glover GH, Solvason HB, Kenna H, Reiss AL, Schatzberg AF. Biol Psychiatry. 2007; 62 (5): 429-37
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, Garlow SJ, Gallop RJ, Ninan PT. J Clin Psychopharmacol. 2007; 27 (6): 614-9
Clinical and biological effects of mifepristone treatment for psychotic depression. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Neuropsychopharmacology. 2006; 31 (3): 628-36
Cortisol circadian rhythm alterations in psychotic major depression. Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF. Biol Psychiatry. 2006; 60 (3): 275-81
A prospective trial of modafinil as an adjunctive treatment of major depression. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. J Clin Psychopharmacol. 2004; 24 (1): 87-90
Predictors of response in anxiety disorders. Solvason HB, Ernst H, Roth W. Psychiatr Clin North Am. 2003; 26 (2): 411-33
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF. J Clin Psychopharmacol. 2003; 23 (1): 27-30
Psychological versus biological clinical interpretation: a patient with prion disease. Solvason HB, Harris B, Zeifert P, Flores BH, Hayward C. Am J Psychiatry. 2002; 159 (4): 528-37
Case report: limbic system activation by intravenous lidocaine in a patient with a complex regional pain syndrome and major depression. Leong MS, Solvason HB. Pain Med. 2000; 1 (4): 358-61
ECT in dissociative identity disorder and comorbid depression. DeBattista C, Solvason HB, Spiegel D. J ECT. 1998; 14 (4): 275-9
A 25-year-old woman with hallucinations, hypersexuality, nightmares, and a rash. Stein SL, Solvason HB, Biggart E, Spiegel D. Am J Psychiatry. 1996; 153 (4): 545-51